More efficient aerosol therapy

June 11, 2015 News Quality by Design - Business & Communications

Aerosol therapy is an important aspect of respiratory care. The drug-delivery efficiency depends on the deposition of the aerosol particles in the lungs of the patients. Unfortunately, lung deposition can be as low as only 10 to 15% of the total, nominal dose.

Determining the deposition characteristics of inhaled drugs is often very challenging for pharmaceutical and biotech companies. Several factors such as disease severity, the inhalation device and the way the patient is breathing influences where and how much inhaled particles end up in the lungs.

FLUIDDA launches the BRONCHOLAB platform providing researchers and clinicians an unparalleled view into the dynamics of the inhaled particles. BRONCHOLAB allows for optimization of the drug formulations and inhalation devices for certain diseases and patient types. Click here to download a 3D-animation visualising the aerosol deposition as a function of the patient’s breathing pattern.

Avatar photo
Quality by Design - Business & Communications

Quality by Design (QbD) - Business & Communications is a team of expert strategists, scientists, communicators, and creatives. Whether you're a part of an innovative startup or an established player, our unique approach will ensure that your company has the best chance of being seen and understood by your target audience: prospects, clients, investors, partners, and more. We don’t just consult; we also help you implement. We share articles on BioVox providing insight into new and established players in the Benelux Life Science ecosystem, from innovations and research breakthroughs through to finance and industry trends.

All posts


* indicates required

Intuit Mailchimp